Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

"Buy Brazilian" gives 25% price premium for home grown innovation

This article was originally published in Scrip

Executive Summary

New rules on bidding for government contracts in Brazil mean that manufacturers can charge up to 25% extra if any innovation relating to the product has taken place in the country. The law is potentially good for the pharmaceutical industry in Brazil, but Interfarma, the R&D-based pharmaceutical industry association there, warns that without a clear definition of innovation, the new law could lead to confusion and expensive legal wrangling for companies.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC013623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel